Hagelberg Stefan, Lee Yuna, Bargman Joanne, Mah Gordon, Schneider Rayfel, Laskin Carl, Eddy Allison, Gladman Dafna, Urowitz Murray, Hebert Diane, Silverman Earl
Divisions of Rheumatology and Nephrology, The Hospital for Sick Children, Toronto, Ontario, Canada.
J Rheumatol. 2002 Dec;29(12):2635-42.
To determine the longterm outcome in children with onset of lupus nephritis before 18 years of age.
Sixty-seven patients with onset of lupus nephritis prior to age 18 were identified. The mean followup time was 11 years (range 5-19). The mean age at diagnosis was 13.2 years (range 4-17). The male:female ratio was 1:3.8. Renal biopsies were classified using the WHO classification. Fifteen patients had Class II, 8 patients Class III, 32 patients Class IV, and 11 patients Class V and one patient refused biopsy. The cohort consists of the 66 patients who had a renal biopsy. Five patients received cyclophosphamide (CYC) and 17 received azathioprine (AZA) as part of the initial treatment of Class IV nephritis. Eight additional patients received CYC because of a flare of disease while receiving AZA, and 8 other patients received AZA because of a flare of disease while taking prednisone therapy.
Four patients died; 6 developed endstage renal disease (ESRD); all but one of the patients who died and/or had ESRD had WHO Class IV [diffuse proliferative glomerulonephritis (DPGN)]; only 2 Caucasians developed ESRD, although 16 out of 36 Caucasians had DPGN; serum creatinine at followup was normal in 84% of the survivors; presently 70% of the patients take less than 7.5 mg prednisone/day and 62% do not take cytotoxic drugs. No patient is currently treated with CYC. All 8 patients with Class III nephritis were taking medication at last followup.
The longterm outcome in this group of children with lupus nephritis, in whom AZA was the most commonly used immunosuppressive agent, was excellent, with 94% patient survival at a mean followup of 11 years. Our results suggest that non-Caucasian patients with pediatric onset lupus nephritis may be at increased risk for renal failure compared to Caucasians.
确定18岁前发病的狼疮性肾炎患儿的长期预后。
确定67例18岁前发病的狼疮性肾炎患者。平均随访时间为11年(范围5 - 19年)。诊断时的平均年龄为13.2岁(范围4 - 17岁)。男女比例为1:3.8。肾活检采用世界卫生组织(WHO)分类法。15例为Ⅱ级,8例为Ⅲ级,32例为Ⅳ级,11例为Ⅴ级,1例拒绝活检。该队列包括66例接受肾活检的患者。5例患者接受环磷酰胺(CYC),17例接受硫唑嘌呤(AZA)作为Ⅳ级肾炎初始治疗的一部分。另外8例患者在接受AZA治疗时因疾病复发而接受CYC,8例其他患者在接受泼尼松治疗时因疾病复发而接受AZA。
4例患者死亡;6例发展为终末期肾病(ESRD);除1例死亡和/或患有ESRD的患者外,其余均为WHO Ⅳ级[弥漫性增殖性肾小球肾炎(DPGN)];只有2名白种人发展为ESRD,尽管36名白种人中有16名患有DPGN;84%的幸存者随访时血清肌酐正常;目前70%的患者每天服用泼尼松少于7.5mg,62%的患者不服用细胞毒性药物。目前没有患者接受CYC治疗。所有8例Ⅲ级肾炎患者在最后一次随访时都在服药。
在这组狼疮性肾炎患儿中,AZA是最常用的免疫抑制剂,长期预后良好,平均随访11年时患者生存率为94%。我们的结果表明,与白种人相比,儿童期发病的狼疮性肾炎非白种人患者肾衰竭风险可能增加。